Ovarian Cancer Clinical Trial

Clinical Trial Finder Ovarian Cancer Trials

EMD 273066 in Patients With Recurrent EpCAM Positive Ovarian, Prostate, Colorectal or Non-small Cell Lung Cancers When First Given Cyclophosphamide

See Locations Near You

Summary

This study is looking at the safety and tolerability of the experimental biological drug EMD 273066 when given with low dose cyclophosphamide to patients with recurring EpCAM positive ovarian, prostate, colorectal or non-small cell lung cancers. EMD 273066 is an experimental biological drug that may increase the immune response to certain cancers. Patients will be enrolled in groups of 3, with each successive group receiving a higher dose if the prior group adequately tolerates the study medication.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Recurrent non-small cell lung, colorectal, ovarian or prostate cancer
No more than two lines of prior chemotherapy
Positive EpCAM expression
Karnofsky Performance Status > 70%
Adequate laboratory results
Normal cardiac stress test

Exclusion Criteria:

Evidence of brain metastases
Pregnant or lactating females
Significant infection
Prior receipt of EMD 273066
Unable to interrupt anti-hypertensive medications 2 days prior to and through each cycle of study medication administration
Uncontrolled hypertension
Previous diagnosis of Addison's disease
Previous diagnosis of an autoimmune disease
Organ transplant
Insulin-dependent diabetes
History of acute pancreatitis
Congestive heart failure

Study is for people with:

Ovarian Cancer

Phase:

Phase 1

Estimated Enrollment:

45

Study ID:

NCT00132522

Recruitment Status:

Completed

Sponsor:

EMD Serono

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 5 Locations for this study

See Locations Near You

City of Hope
Durate California, 91010, United States
Dartmouth Medical School, Pharmacology & Toxicology Dept. of Medicine
Lebanon New Hampshire, 03756, United States
Fox Chase Cancer Oncology Department of Medical Oncology
Philadelphia Pennsylvania, 19111, United States
University of Wisconsin Division of Gynecologic Oncology
Madison Wisconsin, 53792, United States
Centre pluridisciplinaire d'Oncologie
Lausanne Rue du Bugnon, 46, Switzerland
Load More

How clear is this clinincal trial information?

Study is for people with:

Ovarian Cancer

Phase:

Phase 1

Estimated Enrollment:

45

Study ID:

NCT00132522

Recruitment Status:

Completed

Sponsor:


EMD Serono

How clear is this clinincal trial information?

Clinical Trial Resources

Why I’d Choose a Clinical Trial For Myself
Clinical Trials Can be Life-Saving for Some
Promising Immunotherapy Trials for Ovarian Cancer
×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider